Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

Barton, John M.; Bois, John P.; Sarr, Michael G.; Wood, Christina M.; Qin, Rui; Thomsen, Kristine M.; Kendrick, Michael L.; Farnell, Michael B.

doi:10.1007/s11605-009-0849-z

Cited by 86 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preoperative CA 19.9 levels below certain threshold were associated with increased overall and recurrence-free survival (29). The evidence that the chemovirotherapy treatment reduced CA 19.9 levels by 95% was a clear confirmation of the effective reduction in the tumor mass.…”

Section: Discussionmentioning

confidence: 87%

A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models

Weber

Gidekel

Werbajh

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We decided to construct a novel oncolytic adenovirus whose replication was driven by the CDC25B promoter for its use in preclinical models of pancreatic cancer.Experimental Design: We placed the essential E1A gene under control of the CDC25B promoter. Based on preliminary data, we pseudotyped the adenovirus with a chimeric fiber of serotypes 5/3. We investigated the in vitro lytic effect and the in vivo therapeutic efficacy in combination with gemcitabine on human pancreatic tumor xenografts orthotopically growing in nude mice and in tumors growing in Syrian hamsters. We also assessed biochemical markers of hepatic toxicity and CA19.9 levels.Results: AV25CDC exhibited a strong in vitro lytic effect on pancreatic cancer cells. In vivo administration of AV25CDC combined with gemcitabine in mice harboring subcutaneously growing SW1990 pancreatic tumors almost abrogated tumor growth.Nude mice harboring 15-day-old orthotopic tumors, treated intratumorally or systemically with AV25CDC combined with gemcitabine, exhibited 70% to 80% reduction in tumor size compared with control mice that lasted for at least 60 days. Chemovirotherapy treatment induced a return to normal levels of biochemical parameters of hepatic toxicity; these mice exhibited more than 90% reduction in CA19.9 serum levels compared with control. Chemovirotherapy efficacy was confirmed in mice harboring Mia PaCa-2 tumors and in Syrian hamster harboring HaP-T1 tumors. We observed that viral treatment disrupted tumor architecture and induced an increase in MMP-9 activity that might facilitate gemcitabine penetrability.Conclusion: These data demonstrate that AV25CDC is an effective oncolytic agent candidate for pancreatic cancer chemovirotherapy combination.

show abstract

Section: Discussionmentioning

confidence: 87%

A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models

Weber

Gidekel

Werbajh

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Its clinical usefulness in the diagnosis [21], the assessment of resectability [14], monitoring the progression [11] and determining the prognosis of pancreatic cancer has been reported [7-13]. Ferrone et al [20] reported that the preoperative level of CA19-9 was not an independent prognostic factor in patients with resectable pancreatic adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…To date, several studies have reported that the preoperative carbohydrate antigen 19-9 (CA19-9) level, which is a tumor-associated antigen that requires the expression of a sialylated Lewis blood group antigen for expression, is a useful marker for predicting prognosis after resection [5-13]. However, the cutoff value of CA19-9 used to predict prognosis varied among these reports.…”

Section: Introductionmentioning

confidence: 99%

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

et al. 2014

View full text Add to dashboard Cite

BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers. Several studies have reported that the carbohydrate antigen 19-9 (CA19-9) level is a useful marker for predicting the prognosis for PDAC after resection. However, the cutoff value of CA19-9 used to predict prognosis varied among these reports. The aims of this study were to evaluate whether the serum CA19-9 level is a significant predictor for survival and to determine the optimal cutoff value of CA19-9 for predicting prognosis.MethodsA total of 120 consecutive patients who underwent surgery for potentially resectable primary PDAC were retrospectively analyzed. The variables included the following: age, sex, the location of the tumor, the maximal tumor size, the histological differentiation, the margin status, the tumor stage, serum CA19-9 levels, and serum total bilirubin (TBil) levels.ResultsThe overall 1-year survival rate was 62.5%. The receiver operating characteristic (ROC) curve indicated a significant result for the level of CA19-9 in predicting death within 1 year after surgery (Area under the curve (AUC), 0.612; 95% confidence interval (CI), 0.505-0.720; P = 0.040). The optimal cutoff point was 338.45 U/mL (sensitivity, 60.0%; specificity, 66.7%; accuracy, 64.2%). The strongest univariate predictor among the categorized CA19-9 values was CA19-9 greater than or equal to 338.45 U/mL. In the multivariate Cox proportional hazards mode analysis, the serum CA19-9 level, age and the histological differentiation were significant independent prognostic factors that were associated with the overall survival.ConclusionsThe preoperative elevated CA19-9 level is a promising independent factor for predicting a poor prognosis in PDAC, and the optimal cutoff value is 338.45 U/mL.

show abstract

“…Currently, most FDA-approved cancer biomarkers are glycoproteins or carbohydrate antigens (Adamczyk, Tharmalingam, & Rudd, 2012;Barton et al, 2009;Ludwig & Weinstein, 2005). Many of these existing glycoprotein biomarkers could potentially be improved for specificity and sensitivity by incorporating a tumor-specific glycoform.…”

Section: Opportunities and Challengesmentioning

confidence: 99%

Glycosylation and Cancer: Moving Glycomics to the Forefront

Drake

2015

Advances in Cancer Research

View full text Add to dashboard Cite

Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

Abstract: Our findings do not support a cutoff value for CA 19-9 that is associated with margin or lymph node involvement. Preoperative CA 19-9 < or = 120 U/ml is, however, associated with increased overall and recurrence-free survival.

Cited by 86 publications

References 16 publications

A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models

A Novel CDC25B Promoter–Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Glycosylation and Cancer: Moving Glycomics to the Forefront

Contact Info

Product

Resources

About